CAS NO: | 145-13-1 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
50 g | 电议 |
生物活性 | Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor ofcannabinoidCB1receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by theCB1receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also aTRPM3 channelactivator, and also can weakly activateTRPM1 channels[3]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | CB1 receptor stimulation increases brain Pregnenolone levels, which in turn exerts a negative feedback on the activity of the CB1 receptor antagonizing most of the known behavioral and somatic effects of THC. Pregnenolone likely acts as a signaling-specific negative allosteric modulator binding to a site distinct from that occupied by orthosteric ligands. Pregnenolone does not modify agonist binding but only agonist efficacy[1]. | ||||||||||||||||
体内研究 (In Vivo) | Pregnenolone administration (2-6 mg/kg) blocks THC-induced food-intake in Wistar rats and in C57BL/6N mice, and blunts the memory impairment induced by THC in mice, but it does not modify these behaviorsper se. Injections of Pregnenolone (2 and 4mg/kg) before each self-administration session reduce the intake of WIN 55,212-2 and reduce the break-point in a progressive ratio schedule[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 316.48 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C21H32O2 | ||||||||||||||||
CAS 号 | 145-13-1 | ||||||||||||||||
中文名称 | 孕烯醇酮 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 25 mg/mL(78.99 mM;ultrasonic and warming and heat to 60℃) H2O : 0.1 mg/mL(0.32 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|